{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-002346","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.807390+00:00","generated_at":"2026-06-27T03:05:09.708316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Zomedica reports 2021 full-year revenue of $4.1M; net loss $18.4M","bullets":["Total revenue of $4.1M in 2021, vs $0 in 2020; gross margin 73.9%.","Net loss $18.4M ($0.05 diluted EPS) vs $16.9M ($0.19) in 2020.","PulseVet Q4 revenue $4.0M, up 66% YoY as standalone; TRUFORMA Q4 revenue $73k, up 224% QoQ.","Cash and equivalents $195M at Dec 31, 2021 vs $62M a year earlier.","Expected to launch eACTH assay in Q2 2022; evaluating M&A opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-002346","json":"https://secwatch.observer/filing/0001654954-22-002346.json","markdown":"https://secwatch.observer/filing/0001654954-22-002346.md","text":"https://secwatch.observer/filing/0001654954-22-002346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495422002346/0001654954-22-002346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495422002346/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:05:09.708316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}